Navigation Links
Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Johnson & Johnson: PharmaVitae Profile

http://www.reportlinker.com/p0201764/Johnson--Johnson-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial perfor

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2003-15 7

Johnson & Johnson: PharmaVitae forecasts at a glance 8

Strategic insight 9

Managing the boom & bust of 'blockbuster' drugs 9

US small molecule drug sales increase generic exposure 9

Lifecycle management will minimize loss from key products 9

Pipelines in a product-critical for growth of a company on J&J's scale 11

Despite challenges, J&J's outlook appears robust 12

Performance to 2015 will be clear by 2012 12

Diversified business balances risk 14

Wide range of strategic options to seek growth 15

SWOT analysis 18

Strengths 18

Weaknesses 19

Opportunities 20

Threats 21

Table of Contents 22

Table of figures 24

Chapter 3 Quarterly news update 25

Key findings 25

Latest quarterly sales 26

Latest comment 27

Q1 2010 27

Hope for an Alzheimer's breakthrough remains despite Dimebon's failure 27

MRSA drug receives European setback, J&J returns rights 28

Latest prescription pharma product news 30

Q2 2010 30

Q1 2010 30

Q4 2009 30

Q3 2009 31

Q2 2009 33

Q1 2009 34

Latest corporate news 36

Q1 2010 36

Q1 2010 36

Q4 2009 37

Q3 2009 37

Q2 2009 37

Q1 2009 38

Future product milestones 39

Chapter 4 Company introduction 40

Key findings 40

Background 41

Key corporate developments 41

M&A history 42

M&A strategy 44

Current corporate structure 45

Chapter 5 Company sales 46

Key findings 46

Prescription pharmaceutical sales and growth rate analysis, 2003-15 47

Product analysis 49

Product analysis, 2003-09 50

Product analysis, 2009-15 54

Therapy area analysis 59

Geographic analysis 63

Launch/core/expiry analysis 65

Explanation of launch/core/expiry analysis 65

Launch analysis, 2009-15 66

Core analysis, 2009-15 68

Expiry analysis, 2009-15 69

Generics analysis, 2009-15 71

Launch/core/expiry configuration, 2009-15 72

Molecule type analysis 73

Externalization analysis 76

Chapter 6 Company financials 79

Key findings 79

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 80

Operating costs and profit analysis 81

Operating costs and profit analysis, 2003-09 82

Operating cost ratio and profit margin analysis, 2003-09 83

Operating cost ratio and profit margin analysis, 2009-15 84

Operating costs and profit analysis, 2009-15 85

Chapter 7 Key products 87

Key findings 87

Overview 88

Xarelto 89

Summary 89

Sales forecast 90

US launch forecast at the end of 2010 90

Set to revolutionize anticoagulant management 90

Attractive product profile will aid market success 91

Regulatory hurdles remain 91

Invega franchise 93

Summary 93

Sales forecast 94

Limited switching from Risperdal 94

Invega Sustenna will build upon Risperdal Consta's success 95

Generic Invega assumed from 2012 95

Simponi 96

Summary 96

Sales forecast 97

Velcade 98

Summary 98

Sales forecast 99

Growth driven by label expansion 99

Takeda prevented J&J from acquiring Millennium 100

Remicade 101

Summary 101

Sales forecast 102

J&J markets Remicade in the US only 102

Humira has slowed growth of Remicade sales 102

New launches will maintain the growth of J&J's I&I franchise 103

Procrit 104

Summary 104

Sales forecast 105

Decline as market share lost to Aranesp from 2002 105

Safety concerns have hit the wider ESA market 105

Further competition limited to ex-US markets for now 106

Risperdal franchise 107

Summary 107

Sales forecast 108

Success driven by first to market and favorable side effect profile 108

US generics hit Risperdal sales from June 2008 109

Additional products aimed at retaining patients within JNJ's portfolio 109

Prezista 111

Summary 111

Sales forecast 112

Growth strengthened by earlier use 112

Close fit with additional HIV products 112

Chapter 8 Appendix 114

R&D pipeline 114

Remicade sales reconciliation 116

References 116

Abbreviations 117

Exchange rates 118

About Datamonitor 119

About Datamonitor Healthcare 119

Datamonitor consulting 119

Disclaimer 121

List of Tables Table 1: Johnson & Johnson - PharmaVitae forecasts at a glance 8

Table 2: Johnson & Johnson quarterly sales ($m), Q408-Q409 26

Table 3: Johnson & Johnson future product milestones, 2010-12 39

Table 4: Johnson & Johnson product portfolio overview ($m), 2003-09 50

Table 5: Johnson & Johnson product portfolio overview ($m), 2009-15 54

Table 6: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2009-15 62

Table 7: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2009-15 64

Table 8: Johnson & Johnson launch portfolio overview ($m), 2009-15 66

Table 9: Johnson & Johnson core portfolio overview ($m), 2009-15 68

Table 10: Johnson & Johnson expiry portfolio overview ($m), 2009-15 69

Table 11: Johnson & Johnson expiry portfolio overview ($m), 2009-15 71

Table 12: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2009-15 75

Table 13: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2009-15 78

Table 14: Total Johnson & Johnson sales by business unit ($m), 2003-09 80

Table 15: Johnson & Johnson operating revenue/cost analysis ($m), 2003-09 82

Table 16: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2003-09 83

Table 17: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2009-15 84

Table 18: Johnson & Johnson operating revenue/cost analysis ($m), 2009-15 85

Table 19: Johnson & Johnson Key products overview 88

Table 20: Xarelto: overview 89

Table 21: Xarelto]: sales forecast ($m), 2009-15 90

Table 22: Invega: overview 93

Table 23: Invega franchise: sales forecast ($m), 2009-15 94

Table 24: Simponi: overview 96

Table 25: Simponi: sales forecast ($m), 2009-15 97

Table 26: Velcade: overview 98

Table 27: Velcade: sales forecast ($m), 2009-15 99

Table 28: Remicade: overview 101

Table 29: Remicade: sales forecast ($m), 2009-15 102

Table 30: Procrit: overview 104

Table 31: Procrit: sales forecast ($m), 2009-15 105

Table 32: Risperdal: overview 107

Table 33: Risperdal: sales forecast ($m), 2009-15 108

Table 34: Prezista: overview 111

Table 35: Prezista: sales forecast ($m), 2009-15 112

Table 36: Johnson & Johnson's R&D pipeline (Phase I-registration) 114

Table 37: Total Remicade sales forecast ($m), 2009-15 116

Table 38: Exchange rates, 2010 118

List of Figures Figure 1: The PharmaVitae Explorer 3

Figure 2: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Johnson & Johnson's financial performance ($m), 2003-15 7

Figure 4: Lifecycle management strategies boost key J&J franchises, 2003-15 ($m) 10

Figure 5: Johnson & Johnson prescription pharmaceutical sales by stage, 2003-15 ($m) 13

Figure 6: J&J's strategic options for growth 15

Figure 7: Johnson & Johnson SWOT analysis 18

Figure 8: Current corporate structure 42

Figure 9: Current corporate structure 45

Figure 10: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 47

Figure 11: Johnson & Johnson Key product sales ($m), 2003-15 49

Figure 12: Johnson & Johnson key sales growth drivers and resistors ($m), 2003-09 52

Figure 13: Johnson & Johnson key sales growth drivers and resistors ($m), 2009-15 56

Figure 14: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2003-15 59

Figure 15: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2003-15 63

Figure 16: Johnson & Johnson launch/core/expiry configuration ($m), 2009-15 72

Figure 17: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2003-15 73

Figure 18: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2003-15 76

Figure 19: Johnson & Johnson operating revenue/cost analysis ($m), 2002-14 81

To order this report:Pharmaceutical Industry: Johnson & Johnson: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile
2. Reportlinker Adds Genzyme Corporation: PharmaVitae Profile
3. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
4. Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets
5. Reportlinker Adds Actelion Ltd: PharmaVitae Profile
6. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
7. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
8. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
9. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
10. Reportlinker Adds The Impact of US Healthcare Reform on Pharma: Analyzing the Effects
11. Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016 Potrero ... system, is pleased to announce the appointment of George ... San Antonio, TX , WellMed is ... servicing over 200,000 patients and HMO members in ... founding WellMed in 1990 out of his own internal medicine ...
(Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article published February ... loss dietary supplement, is being recalled due to the discovery that it contains dangerous ... not a single supplement on the market proven to help people safety lose excess ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Registered nurses, licensed ... CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, February ... in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who will ...
(Date:2/11/2016)... (PRWEB) , ... February 12, 2016 , ... The ... is up from 0.416 in 2013. The SJR uses data taken from the Scopus ... account both the number of citations received by the journal over a three year ...
(Date:2/11/2016)... ... 11, 2016 , ... The Chartis Group, a national advisory ... in the “2015/2016 Best in KLAS: Software and Services” report in two categories: ... and insights firm on a global mission to improve healthcare delivery by amplifying ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader ... to announce the promotions of Allison Kelly to executive vice president of the ... vice president of North American capital sales, and Wendy Oseas to vice president ...
Breaking Medicine News(10 mins):